OncoHost, a technology company focused on precision medicine, announced on Monday that the Business Intelligence Group has named OncoHost as a winner in the 2026 BIG Innovation Awards in the Health category.
Additionally, OncoHost was selected as a Top 10 Innovator – Small Business, reflecting the company's leadership in developing clinically impactful technologies.
OncoHost was recognised for its PROphet platform, an AI-driven plasma-proteomics solution designed to help oncologists predict clinical benefit and therapy-related toxicity from a single pre-treatment blood test. Its first commercial offering, PROphetNSCLC, guides first-line immunotherapy decision-making in metastatic non-small cell lung cancer (NSCLC) by revealing host-response insights that extend beyond tumour-only biomarkers.
The BIG Innovation Awards are designed to honour organisations, products, and leaders transforming industries through applied innovation, intelligent platforms, and measurable real-world impact.
Datroway approved in EU for first-line metastatic triple-negative breast cancer
10x Genomics and Lausanne University Hospital to collaborate on cancer care research
BeOne Medicines expands US manufacturing with USD300m investment
GSK's Jideytro (zidesamtinib) gains US approval for previously treated ROS1-positive NSCLC
Kelun-Biotech's Phase III study of sac-TMT in combination with pembrolizumab meets primary endpoint
AstraZeneca signs global licence deal with Dizal for lung cancer drug Zegfrovy
Insilico initiates Rentosertib Phase III clinical trial for idiopathic pulmonary fibrosis
Genentech reports positive Phase III results for divarasib in KRAS G12C lung cancer
Abbisko Therapeutics and AstraZeneca collaborate to conduct combination clinical trial for NSCLC